Favorable Outcomes with New Generation Transcatheter Heart Valves in Bicuspids

Original Title: Bicuspid Aortic Valve Stenosis Favorable Early Outcomes UIT a Next-Generation Transcatheter Heart Valve in a Multicenter Study. Reference: Gidon Y. Perlman J Am Coll Cardiol Interv 2016;9:817-24

Courtesy of Dr. Carlos Fava.

Congenital bicuspid aortic valves are infrequent and are associated with severe calcification in elderly patients.

Transcatheter aortic valve replacement to treat bicuspid aortic stenosis is challenging because of their anatomical characteristics and there is not enough evidence on its outcomes.

This study included 51 patients with bicuspid aortic valves receiving an Edwards SAPIENS 3.

Mean patient age was 76 and little more than half were women with STS score 5.2±3.7%.

The procedure was done in 20 patients under sedation and local anesthetics, two via carotid access and the rest via femoral.

There were no deaths, malposition, embolization, second valves or conversion to surgery.

At 30 days, the gradient decreased from 49.4±16 mmHg at baseline to 11.2±4.7 mmHg, and the area increased from 0.7±0.2 cm2 to 1.7±0.3 cm2. There was none/trivial aortic regurgitation in 32 patients and none presented moderate or severe regurgitation.

During the first month, there were 2 deaths, 2 major vascular complications and 12 patients required a definite pacemaker.

The need for a definite pacemaker was associated with implantation >8 mm below annulus level (low implantation, 55% need for pacemaker vs. 10% higher implantation; p=0.01).

Conclusion
TAVI in bicuspid valves with new generation devices was feasible and effective with a favorable performance and no cases of moderate or severe aortic regurgitation.

Editorial Comment
Bicuspid valves are different in morphology, are more calcified and are associated with moderate and severe aortic regurgitation.

New generation valves improve performance and encourage us to advance with this group, improving accuracy of position implantation position in order to avoid pacemaker implantation after TAVI.
Courtesy of Dr. Carlos Fava.
Interventional Cardiologist
Favaloro Foundation – Buenos Aires

More articles by this author

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...